Search

Your search keyword '"Zherebtsova, Vera"' showing total 17 results
Start Over Author "Zherebtsova, Vera"
17 results on '"Zherebtsova, Vera"'

1. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.

Author

Jabbour, Elias, Oehler, Vivian G., Koller, Paul B., Jamy, Omer, Lomaia, Elza, Hunter, Anthony M., Uspenskaya, Olga, Samarina, Svetlana, Mukherjee, Sudipto, Cortes, Jorge E., Baer, Maria R., Zherebtsova, Vera, Shuvaev, Vasily, Turkina, Anna, Davydkin, Igor, Guo, Huanshan, Chen, Zi, Fu, Tommy, Jiang, Lixin, and Wang, Cunlin

Published
2025
Full Text
View/download PDF

2. Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).

Author

Hungria, Vania, primary, Robak, Pawel, additional, Hus, Marek, additional, Fu, Chengcheng, additional, Zherebtsova, Vera, additional, Ward, Christopher, additional, de Almeida, Ana Carolina, additional, Ho, P. Joy, additional, Hajek, Roman, additional, Cerchione, Claudio, additional, Pirooz, Nicholas, additional, McKeown, Astrid, additional, Baig, Hena, additional, Eccersley, Lydia, additional, Pompilus, Farrah, additional, McNamara, Simon, additional, Lin, Chee Paul, additional, Roy-Ghanta, Sumita, additional, Opalinska, Joanna, additional, and Mateos, Maria-Victoria, additional

Published
2024
Full Text
View/download PDF

3. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).

Author

Mateos, Maria-Victoria, primary, Robak, Pawel, additional, Hus, Marek, additional, Xia, Zhongjun, additional, Zherebtsova, Vera, additional, Ward, Christopher, additional, Ho, P. Joy, additional, Hajek, Roman, additional, Kim, Kihyun, additional, Dimopoulos, Meletios A., additional, Cerchione, Claudio, additional, Riccio, Antonio, additional, McKeown, Astrid, additional, Rogers, Rachel, additional, Baig, Hena, additional, Eccersley, Lydia, additional, Roy-Ghanta, Sumita, additional, Opalinska, Joanna, additional, and Hungria, Vania, additional

Published
2024
Full Text
View/download PDF

4. Abatacept/Tacrolimus or Abatacept/Tacrolimus/Post-Transplant Cyclophosphamide Are Safe and Highly Effective in Preventing Graft-Versus-Host Disease in Matched or Mismatched Donor Peripheral Blood Stem Cell Transplantation

Author

Vorobyev, Vladimir I., primary, Subora, Anton Yu., additional, Oleinik, Yulia A., additional, Butaev, Lev S., additional, Zherebtsova, Vera A., additional, Kisilichina, Darya G., additional, Ulyanova, Margarita A., additional, Urnova, Evdokiya S., additional, Sukhareva, Alena M., additional, and Bulusov, Matvei P., additional

Published
2022
Full Text
View/download PDF

5. MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Victoria, Maria, Robak, Pawel, Hus, Marek, Fu, ChengCheng, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, de Almeida, Ana Carolina, Hajek, Roman, Kim, Kihyun, Dimopoulos, Meletios, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Kazeem, Benga, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, and Hungria, Vania

Published
2024
Full Text
View/download PDF

6. MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Author

Hungria, Vania, Robak, Pawel, Hus, Marek, Fu, ChengCheng, Zherebtsova, Vera, Ward, Christopher, de Almeida, Ana Carolina, Ho, P. Joy, Hajek, Roman, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Baig, Hena, Eccersley, Lydia, Pompilus, Farrah, McNamara, Simon, Paul Lin, Chee, Roy-Ghanta, Sumita, Opalinska, Joanna, and Victoria, Maria

Published
2024
Full Text
View/download PDF

7. CML-400 Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Author

Jabbour, Elias, Oehler, Vivian G., Koller, Paul B., Jamy, Omer, Lomaia, Elza, Hunter, Anthony M., Uspenskaya, Olga, Samarina, Svetlana, Mukherjee, Sudipto, Cortes, Jorge E., Baer, Maria R., Zherebtsova, Vera, Shuvaev, Vasily, Turkina, Anna, Davydkin, Igor, Guo, Huanshan, Chen, Zi, Fu, Tommy, Jiang, Lixin, Wang, Cunlin, Wang, Hengbang, Yang, Dajun, Zhai, Yifan, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

8. DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mateos, Maria Victoria, Robak, Pawel, Hus, Marek, Fu, ChengCheng, Zherebtsova, Vera, Ward, Christopher, Joy Ho, P., Carolina de Almeida, Ana, Hajek, Roman, Kim, Kihyun, Dimopoulos, Meletios, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Kazeem, Benga, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, and Hungria, Vania

Published
2024
Full Text
View/download PDF

9. Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Author

Hungria, Vania, Robak, Pawel, Hus, Marek, Fu, ChengCheng, Zherebtsova, Vera, Ward, Christopher, Carolina de Almeida, Ana, Joy Ho, P., Hajek, Roman, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Baig, Hena, Eccersley, Lydia, Pompilus, Farrah, McNamara, Simon, Paul Lin, Chee, Roy-Ghanta, Sumita, Opalinska, Joanna, and Victoria Mateos, Maria

Published
2024
Full Text
View/download PDF

10. Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Author

Jabbour, Elias, Oehler, Vivian G., Koller, Paul B., Jamy, Omer, Lomaia, Elza, Hunter, Anthony M., Uspenskaya, Olga, Samarina, Svetlana, Mukherjee, Sudipto, Cortes, Jorge E., Baer, Maria R., Zherebtsova, Vera, Shuvaev, Vasily, Turkina, Anna, Davydkin, Igor, Guo, Huanshan, Chen, Zi, Fu, Tommy, Jiang, Lixin, Wang, Cunlin, Wang, Hengbang, Yang, Dajun, Zhai, Yifan, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

12. Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Author

Vorobyev, Vladimir I., primary, Gemdzhian, Eduard G., additional, Fedorova, Liudmila V., additional, Mikhailova, Natalia B., additional, Ilyasov, Ridvan K., additional, Kaleikina, Liliia P., additional, Trubyakova, Olga S., additional, Kaplanov, Kamil D., additional, Melnichenko, Elena V., additional, Martynova, Elena V., additional, Yakovleva, Elena P., additional, Li, Olga Yu., additional, Tarasenko, Elena V., additional, Chumakova, Elena P., additional, Bulieva, Natalia B., additional, Nesterova, Ekaterina S., additional, Margolin, Oleg V., additional, Zherebtsova, Vera A., additional, Butaev, Lev S., additional, and Ptushkin, Vadim V., additional

Published
2021
Full Text
View/download PDF

13. Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Author

Jabbour, Elias, Kantarjian, Hagop M., Koller, Paul B., Jamy, Omer, Oehler, Vivian G., Lomaia, Elza, Hunter, Anthony M., Uspenskaya, Olga, Samarina, Svetlana, Mukherjee, Sudipto, Baer, Maria R., Zherebtsova, Vera, Shuvaev, Vasily, Turkina, Anna, Davydkin, Igor, Cortes, Jorge, Guo, Huanshan, Chen, Zi, Fu, Lei, Wang, Hengbang, Jiang, Lixin, Wang, Cunlin, Yang, Dajun, and Zhai, Yifan

Published
2023
Full Text
View/download PDF

14. Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Author

Vorobyev, Vladimir I., primary, Zherebtsova, Vera A., additional, Dubrovin, Egor I., additional, Bychenkova, Liudmila A., additional, Butaev, Lev S., additional, Muha, Larisa A., additional, Kochkareva, Yulia B., additional, Ivanova, Valentina L., additional, Nikitin, Eugene A., additional, Tumyan, Gayane, additional, Doronin, Vadim A, additional, Krijanovski, Oleg I., additional, and Ptushkin, Vadim, additional

Published
2019
Full Text
View/download PDF

15. First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial

Author

Stadnik, Elena, primary, Strugov, Vladimir, additional, Silina, Tatyana, additional, Ilyina, Natalya, additional, Virts, Yulia, additional, Badaev, Renat, additional, Kuchma, Galina, additional, Volodicheva, Elena, additional, Sycheva, Tatyana, additional, Kaporskaya, Tatyana, additional, Kaplanov, Kamil, additional, Glonina, Natalya, additional, Anchukova, Lyubov, additional, Byalik, Tatyana, additional, Samoilova, Olga, additional, Kirillova, Elena, additional, Shklyaev, Sergey, additional, Mirolubova, Yulia, additional, Nikulina, Tatyana, additional, Rumyantsev, Andrey, additional, Proydakov, Andrey, additional, Lysenko, Irina, additional, Melnichenko, Vladimir, additional, Esefeva, Natalya, additional, Ksenzova, Tatyana, additional, Davidkin, Igor, additional, Vasilyeva, Olga, additional, Ochirova, Oksana, additional, Rukavitsyn, Oleg, additional, Bulieva, Natalya, additional, Zherebtsova, Vera, additional, Gubkin, Andrey, additional, Bogdanova, Yulia, additional, Chebykina, Irina, additional, Shukaeva, Elena, additional, and Zaritskey, Andrey, additional

Published
2014
Full Text
View/download PDF

16. Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy

Author

Vorobyev, Vladimir I., primary, Lorie, Yuri Yu., additional, Zvonkov, Evgenii' E., additional, Gemdjian, Eduard G., additional, Magomedova, Aminat U., additional, Melikyan, Anait L., additional, Mangasarova, Jana K., additional, Gribanova, Elena O., additional, Zherebtsova, Vera A., additional, Kravchenko, Sergey K., additional, and Savchenko, Valeri G., additional

Published
2012
Full Text
View/download PDF

17. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

Author

Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, and Mateos MV

Subjects
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Kaplan-Meier Estimate, Neoplasm, Residual, Disease Progression, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bortezomib administration & dosage, Bortezomib adverse effects, Dexamethasone administration & dosage, Dexamethasone adverse effects, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Progression-Free Survival
Abstract

Background: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies., Methods: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival. Key secondary end points were overall survival, response duration, and minimal residual disease (MRD)-negative status., Results: In total, 494 patients were randomly assigned to receive BVd (243 patients) or DVd (251 patients). At a median follow-up of 28.2 months (range, 0.1 to 40.0), median progression-free survival was 36.6 months (95% confidence interval [CI], 28.4 to not reached) in the BVd group and 13.4 months (95% CI, 11.1 to 17.5) in the DVd group (hazard ratio for disease progression or death, 0.41; 95% CI, 0.31 to 0.53; P<0.001). Overall survival at 18 months was 84% in the BVd group and 73% in the DVd group. An analysis of the restricted mean response duration favored BVd over DVd (P<0.001). A complete response or better plus MRD-negative status occurred in 25% of the patients in the BVd group and 10% of those in the DVd group. Grade 3 or higher adverse events occurred in 95% of the patients in the BVd group and 78% of those in the DVd group. Ocular events were more common in the BVd group than in the DVd group (79% vs. 29%); such events were managed with dose modifications, and events of worsening visual acuity mostly resolved., Conclusions: As compared with DVd therapy, BVd therapy conferred a significant benefit with respect to progression-free survival among patients who had relapsed or refractory multiple myeloma after at least one line of therapy. Most patients had grade 3 or higher adverse events. (Funded by GSK; DREAMM-7 ClinicalTrials.gov number, NCT04246047; EudraCT number, 2018-003993-29.)., (Copyright © 2024 Massachusetts Medical Society.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results